PMV Pharmaceuticals (PMVP) Corporate presentation summary

Harnessing p53 Y220C mutation for cancer therapy

• Lead candidate rezatapopt is a first-in-class, oral p53 Y220C reactivator targeting a previously undruggable mutation found in 2.9% of ovarian cancers and 1% of all solid tumors.

• TP53 Y220C mutation is present in ~12,000 addressable 2L+ patients in the US and EU4/UK, with broad identification possible via standard NGS panels.

Clinical efficacy and safety of rezatapopt

• Phase 2 PYNNACLE interim data show a 34% overall response rate (ORR) across all cohorts and 46% ORR in ovarian cancer, with median duration of response of 7.6 and 8.0 months, respectively.

• Responses observed in heavily pre-treated, poor prognosis patients; 40% remain on treatment, with rapid median time to response of 1.3 months.

• Safety profile is favorable, with most treatment-related adverse events (TRAEs) being Grade 1/2 and manageable; only 4% discontinued due to TRAEs.

• Significant decreases in ctDNA TP53 Y220C variant allele frequency observed in responders, supporting on-target activity.

Registrational and commercial strategy

• Pivotal Phase 2 study is ongoing, enrolling ~200 patients across five cohorts, with ovarian cancer as the lead indication.

• NDA submission for platinum-resistant/refractory ovarian cancer planned for 1Q2027, with potential US launch the same year.

• Addressable market for 2L+ TP53 Y220C ovarian cancer estimated at $350–420M in the US and $520–630M globally.

• Expansion opportunities exist in breast, endometrial, and other solid tumors, as well as in combination regimens.